Josh Baltzell

Josh is a Venture Partner at healthcare investment manager Sightline Partners, which provides late-stage medical device and diagnostic companies with capital.

Josh has over 25 years of experience in the healthcare industry, varying from product development and innovation to mergers and acquisitions to investing.

He has been a private equity investor since 2004. Josh previously served as a Managing Director at venture capital firm Split Rock Partners and a lead investor and board member for healthcare companies with an aggregate, realized value of over $2 billion. His venture investment track record includes the acquisition of Ardian by Medtronic for $800 million, Stryker’s sale of Entellus Medical for $662 million, Medtronic’s acquisition of RF Surgical for $235 million, and Allergan’s purchase of SkinMedica for $250 million. He previously worked at St. Paul Venture Capital, Piper Jaffray’s investment banking group, and Boston Scientific.

As a Board Director at Aegea, Colorescience, Koya Medical, Magnolia Medical, and ViewPoint Medical, Josh helps those companies focused on addressing underserved healthcare challenges.